published meta-analysis   sensitivity analysis   studies

remdesivir in COVID-19 - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsCAP-China (Wang et al.), 2020 1.10 [0.49; 2.45] GS-US-540-5774, 10 days, 2020 0.77 [0.17; 3.50] GS-US-540-5774, 5 days, 2020 0.52 [0.09; 2.86] NIH NIAID ACTT-1, 2020 0.70 [0.47; 1.04] SOLIDARITY (remdesivir), 2020 0.95 [0.81; 1.11] 0.91[0.79; 1.05]CAP-China (Wang et al.), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, NIH NIAID ACTT-1, 2020, SOLIDARITY (remdesivir), 202050%8,917moderatenot evaluable deaths (time to event analysis only)detailed resultsNIH NIAID ACTT-1, 2020 0.70 [0.47; 1.04] SOLIDARITY (remdesivir), 2020 0.95 [0.81; 1.11] 0.86[0.65; 1.14]NIH NIAID ACTT-1, 2020, SOLIDARITY (remdesivir), 2020249%7,897moderatenot evaluable clinical improvementdetailed resultsCAP-China (Wang et al.), 2020 1.23 [0.87; 1.74] GS-US-540-5774, 10 days, 2020 1.16 [0.77; 1.74] GS-US-540-5774, 5 days, 2020 1.65 [1.09; 2.49] NIH NIAID ACTT-1, 2020 1.32 [1.12; 1.55] 1.32[1.16; 1.50]CAP-China (Wang et al.), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, NIH NIAID ACTT-1, 202040%2,092moderatenot evaluable clinical improvement (14-day)detailed resultsCAP-China (Wang et al.), 2020 1.21 [0.64; 2.28] GS-US-540-5774, 10 days, 2020 1.58 [1.01; 2.47] GS-US-540-5774, 5 days, 2020 1.56 [1.00; 2.44] 1.49[1.13; 1.98]CAP-China (Wang et al.), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 202030%1,020moderatenot evaluable clinical improvement (28-day)detailed resultsCAP-China (Wang et al.), 2020 1.37 [0.79; 2.39] GS-US-540-5774, 10 days, 2020 1.88 [1.03; 3.42] GS-US-540-5774, 5 days, 2020 1.75 [0.97; 3.17] 1.64[1.17; 2.29]CAP-China (Wang et al.), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 202030%1,020moderatenot evaluable clinical improvement (7-day)detailed resultsCAP-China (Wang et al.), 2020 0.99 [0.18; 5.51] GS-US-540-5774, 10 days, 2020 1.03 [0.69; 1.53] GS-US-540-5774, 5 days, 2020 1.53 [1.01; 2.34] 1.23[0.93; 1.64]CAP-China (Wang et al.), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 202030%1,020moderatenot evaluable clinical improvement (time to event analysis only)detailed resultsCAP-China (Wang et al.), 2020 1.23 [0.87; 1.74] 1.23[0.87; 1.74]CAP-China (Wang et al.), 202010%237lownot evaluable death or ventilationdetailed resultsSOLIDARITY (remdesivir), 2020 0.97 [0.85; 1.10] 0.97[0.85; 1.10]SOLIDARITY (remdesivir), 202010%5,451moderatenot evaluable ventilationdetailed resultsSOLIDARITY (remdesivir), 2020 1.04 [0.87; 1.23] 1.04[0.87; 1.23]SOLIDARITY (remdesivir), 202010%4,964moderatenot evaluable AE leading to drug discontinuationdetailed resultsCAP-China (Wang et al.), 2020 2.43 [0.79; 7.45] 2.43[0.79; 7.45]CAP-China (Wang et al.), 202010%233lownot evaluable serious adverse eventsdetailed resultsCAP-China (Wang et al.), 2020 0.64 [0.33; 1.23] NIH NIAID ACTT-1, 2020 0.72 [0.54; 0.96] 0.71[0.55; 0.92]CAP-China (Wang et al.), 2020, NIH NIAID ACTT-1, 202020%1,296moderatenot evaluable deep vein thrombosisdetailed resultsCAP-China (Wang et al.), 2020 0.50 [0.03; 8.10] NIH NIAID ACTT-1, 2020 0.64 [0.23; 1.81] 0.62[0.23; 1.64]CAP-China (Wang et al.), 2020, NIH NIAID ACTT-1, 202020%1,296moderatenot evaluable elevated liver enzymesdetailed resultsCAP-China (Wang et al.), 2020 0.36 [0.13; 1.01] NIH NIAID ACTT-1, 2020 0.67 [0.38; 1.18] 0.58[0.34; 0.97]CAP-China (Wang et al.), 2020, NIH NIAID ACTT-1, 202026%1,296moderatenot evaluable hyperbilirubinemiadetailed resultsCAP-China (Wang et al.), 2020 1.09 [0.42; 2.79] NIH NIAID ACTT-1, 2020 0.84 [0.30; 2.34] 0.97[0.48; 1.93]CAP-China (Wang et al.), 2020, NIH NIAID ACTT-1, 202020%1,296moderatenot evaluable pulmonary embolismdetailed resultsCAP-China (Wang et al.), 2020 0.50 [0.03; 8.10] NIH NIAID ACTT-1, 2020 0.96 [0.19; 4.80] 0.82[0.20; 3.29]CAP-China (Wang et al.), 2020, NIH NIAID ACTT-1, 202020%1,296moderatenot evaluable renal impairmentdetailed resultsCAP-China (Wang et al.), 2020 1.01 [0.03; 30.33] NIH NIAID ACTT-1, 2020 1.02 [0.64; 1.61] 1.02[0.64; 1.61]CAP-China (Wang et al.), 2020, NIH NIAID ACTT-1, 202020%1,296moderatenot evaluable0.25.01.0relative treatment effectwww.metaEvidence.org2021-01-20 14:19 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 87,95,94,90,91,97 - treatments: 510 - roots T: 290